Alzheimer: Una mirada neurofisiológica y patológica de la enfermedad. ¿Dónde se origina la enfermedad?

Rugeles Castañeda, Andrea

dc.contributor.advisor	Suárez Baquero, Alejandra
dc.contributor.author	Rugeles Castañeda, Andrea
dc.date.accessioned	2012-05-15T19:16:46Z
dc.date.available	2012-05-15T19:16:46Z
dc.date.created	2007
dc.date.issued	2012-05-15
dc.identifier.citation	Algado, M.T., et al.(1997). Familia y enfermedad de Alzheimer.Una perspectiva cualitativa. Anales de Psicología, (13), p.21.
dc.identifier.citation	Bartus, RT.(2000) On neurodegenerative diseases, models, and treatment strategies:lessons learned and lessons forgotten a generation following the cholinergic hupothesis. Exp Neurol (163).
dc.identifier.citation	Bermejo, FP. (1998) La enfermedad de Alzheimer. Medicina Interna (16).
dc.identifier.citation	Blasco, I. & Grubeck-Loebenstein, B.(2003). Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer’s disease. Drugs Aging.(20).p.105.
dc.identifier.citation	Blasco, I. et al.(2004). How chronic inflammation affects the brain and supports the development of Alzheimer’s disease in old age: the role of microglia and astrocytes. Aging Cell.(3).
dc.identifier.citation	Buffil, E. & Blesa, R. (2006) Alzheimer’s Disease And Brain Evolution: Is Alzheimer's Disease An Example Of Antagonistic Pleiotropy?. Revista de Neurología (42).pp.25-26
dc.identifier.citation	Campion, D. et al.(1999). Early-onset autosomal dominant Alzheimer disease: prevalence,genetic heterogeneity, and mutation spectrum. American Journal Hum Genet.(65).p.668.
dc.identifier.citation	Cruts, M. & Van Broeckhoven, C.(1998).Presenilin mutations in Alzheimer’s disease.Hum Mutat. (11).
dc.identifier.citation	Farrer, LA. et al.(1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis.
dc.identifier.citation	APOE and Alzheimer Disease Meta Analysis Consortium. JAMA.(278).p.1350.
dc.identifier.citation	Flynn, DD. Et al.(1995). Differential alterations in muscarinic receptor subtypes in Alzheimer’s disease: implications for cholinergicbased therapies. Life Sci (56).p.86.
dc.identifier.citation	Forstl, H. et al. (1992).Clinical and neuropathological correlatesof depression in Alzheimer’s disease. Psychol Med.(22).
dc.identifier.citation	Gálvez, R. et al. (2000) Epidemiología de la enfermedades degenerativas del sistema nervioso. Barcelona: ed. Masson Salvat-Medicina.
dc.identifier.citation	Gómez,T. et al.(1997).Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. (41).p.19
dc.identifier.citation	Gottfries, CG. et al.(1995) Neuropeptides and Alzheimer’s disease. Eur Neuropsychopharmacol.(5).
dc.identifier.citation	Hardy, J.et al.(1998).Genetic dissection of Alzheimer’s disease and related dementias: amyloid and its relationship to tau. Nat Neurosci. (1).p.371. Hoenicka, J. (2006) Genes In Alzheimer’s Disease.Rev Neurol.(42).pp.302-303
dc.identifier.citation	Huse, JT. & Doms, RW. (2000). Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer’s disease. Mol Neurobiol. (22).p.88.
dc.identifier.citation	Ikonomovic, MD.et al.(1999). Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer’s disease. Exp Neurol.(160)
dc.identifier.citation	Kordower, JH. Et al. (2001). Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol (49).
dc.identifier.citation	Lanctot, KL. et al (2001) Role of serotonin in the behavioraland psychological symptoms of dementia. Journal of Neuropsychiat Clinical. (13).p.521.
dc.identifier.citation	Lewis, J. et al.(2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. (293).
dc.identifier.citation	Li, YM. et al.(2000).Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature.(405)
dc.identifier.citation	López, L. & DeKosky, S. (2003). Neuropatología de la enfermedad de Alzheimer y del deterioro cognitivo leve. Revista Neurologica. (37).p158-159.
dc.identifier.citation	Maelicke, A. et al.(2000) Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer’s disease. Behav Brain Res. (113).
dc.identifier.citation	Martín, CM.et al.(1999). Alpha4 but not Alpha3 and Alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer’s disease. Journal Neurochem. (73).
dc.identifier.citation	Martin, JB.(1999). Molecular basis of the neurodegenerative disorders. New England Journal Med.(340).
dc.identifier.citation	Marutle, A, et al.(1999) Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor 670/671 mutation. Journal Neurochem.(72).
dc.identifier.citation	McGeer, EG. & McGeer, PL.(1997). The role of the immune system in neurodegenerative disorders. Mov Disord.(12).
dc.identifier.citation	McGeer, EG. & McGeer, PL.(2003). Inflammatory processes in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry.(27).
dc.identifier.citation	Mesulam M. (1995).Structure and function of cholinergic pathways in the cerebral cortex, limbic system, basal ganglia, and thalamus of the human brain. New York: Raven Press.p.139.
dc.identifier.citation	Mesulam, M. (2000) Principles of behavioral and cognitive neurology. NewYork: Oxford University Press.
dc.identifier.citation	Minton, L. et al.(1997). Somatostatin and neuropeptide Y in cerebrospinal fluid correlations with severity of disease and clinical signs in Alzheimer’s disease and frontotemporal dementia. Dement Geriatr Cogn Disord.(8).
dc.identifier.citation	Morillo, L. (2006) Alzheimer: ¿Qué es la Enfermedad?. Abc Medicus. (40).p.4.
dc.identifier.citation	Nesse, R. & Williams, G. (1994) Why we get sick. New York: Vintage BooksRandom House.
dc.identifier.citation	Nordberg, A. (2001). Nicotonic receptor abnormalities of Alzheimer’s disease:Therapeutic implications. Biol Psychiatry. (49).p.200.
dc.identifier.citation	Nordberg, A. et al. (1998). Longterm tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG and cognitive abilities. Alzheimer Diseas Assoc Disord. (12).
dc.identifier.citation	Paterson,D. & Nordberg, A. (2000). Neural nicotinic receptors in the human brain. Progress in Neurobiology. (61).
dc.identifier.citation	Poirier, J.(1994).Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci.(17).p.528.
dc.identifier.citation	Price, JL. et al.(2001). Neuron number in the entorhinal cortex and CAI in preclinical Alzheimer’s disease. Arch Neurol. (58).p.156.
dc.identifier.citation	Rogaev, EI. et al.(1995).Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature. (376).
dc.identifier.citation	Schellenberg, GD.et al.(1992).Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science.(258).
dc.identifier.citation	Smith, E. et al. (1999) Evolutionary medicine. New York:Oxford University Press. p.25
dc.identifier.citation	Strittmatter, WJ.et al.(1993).Apolipoprotein E: high-avidity binding to betaamyloid and increased frequency of type 4 allele in late-onset failial Alzheimer disease. Proc Natl Acad Sci.(90).p.197.
dc.identifier.citation	Tárraga, L. et al. “Estimulación cognitiva y memoria” Disponible en red: www.infodoctor.org/alzheimer.htm, extraido el 20 de Abril de 2006}. Toledo, M. (2006) Inflamación y Enfermedad de Alzheimer. Revista de Neurología (42).pp.433, 435.
dc.identifier.citation	Thomas, M.& Isaac, M. (1987) Alois Alzheimer: a memoir. Trends Neurosci (10).
dc.identifier.citation	Van Broeckhoven, C.et al.(1992). Mapping of a gene predisposing to earlyonset Alzheimer’s disease to chromosome 14q24.3. Nat Genet.(2)
dc.identifier.citation	Van Hoesen, GW. & Hyman, BT. (1990) Hippocampal formation: anatomy and the patterns of patholog Alzheimer’s disease. Brain Res (83).p.448.
dc.identifier.citation	Vilalta, J. et al. (2000) Prevalencia de demencias en una zona rural. Revista Neurológica. (30).
dc.identifier.citation	Wilson, RS. et al.(2002). The apolipoprotein E 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol.(59).
dc.identifier.citation	Zorumski,CF. & Isenberg, KE. (1991) Insights into the structure and function of GABA benzodiazepine receptors: ion channels and psychiatry. American Journal of Psychiatry. (148).p.162.
dc.identifier.citation	“Neurología, Enfermedad de Alzheimer” Disponible en red {www.iqb.es/neurologia/enfermedades/alzheimer/enfermedadpaciente/ e003.htm, extraido el 5 de Abril de 2006}
dc.identifier.citation	“Historia de una efermedad” Disponible en red {www. elmundosalud.elmundo.es/elmundosalud/especiales/2004/04/alzheimer/ historia.htm, extraido 10 de Marzo de 2006}
dc.identifier.citation	“La enfermedad de Alzheimer, Historia” Disponible en red {www.grunenthal.es/cw/es_ES/html/cw_es_es_patient.jhtml?CatId=cw _es_es_patient_d_01b, extraído el 7 de Abril de 2006}
dc.identifier.citation	“Stages of Alzheimer's Disease, Alzheimer's Association” Disponible en red {http://www.alz.org/aboutad/stages.asp, extraido 7 de Abril de 2006}
dc.identifier.uri	http://hdl.handle.net/10818/2168
dc.description	44 Páginas.
dc.description.abstract	El Alzheimer es una enfermedad degenerativa progresiva del cerebro, se manifiesta por la desorientación y perdida de memoria. Fue descrita en 1906, por Alois Alzheimer. Anatomopatológicamente, se caracteriza por la aparición de placas seniles conformadas por la acumulación de la molécula amieloide, producto de la APP. Están implicados los cromosomas 1, 14, 19 y 21. El cromosoma 19, sintetiza la proteína activadora APOE, responsable del inicio de la enfermedad. Se han evidenciado anomalías inmunológicas debido a que la molécula amieloide no suele encontrarse en los vertebrados, por lo tanto éstos carecen de enzimas necesarias para degradarla; ello podría explicar la progresiva acumulación de amieloide; motivo por el cual las células de la microglía se activan pero no responden inmunológicamente.	es_CO
dc.language.iso	es	es_CO
dc.publisher	Universidad de La Sabana
dc.source	Universidad de la Sabana
dc.source	Intellectum Repositorio Universidad de la Sabana
dc.subject	Enfermedad de Alzheimer	es_CO
dc.subject	Enfermedades del sistema nervioso	es_CO
dc.title	Alzheimer: Una mirada neurofisiológica y patológica de la enfermedad. ¿Dónde se origina la enfermedad?	es_CO
dc.type	bachelorThesis
dc.publisher.program	Psicología
dc.publisher.department	Facultad de Psicología
dc.identifier.local	88334
dc.identifier.local	TE04585
dc.type.local	Tesis de pregrado
dc.type.hasVersion	publishedVersion
dc.rights.accessRights	openAccess
dc.creator.degree	Psicólogo